Tom Appio'un ücretlendirmesi Bausch Health Companies'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2025	n/a	n/a	-US$40m
Dec 31 2024	US$16m	US$1m	-US$46m
Sep 30 2024	n/a	n/a	-US$178m
Jun 30 2024	n/a	n/a	-US$471m
Mar 31 2024	n/a	n/a	-US$455m
Dec 31 2023	US$16m	US$1m	-US$592m
Sep 30 2023	n/a	n/a	-US$963m
Jun 30 2023	n/a	n/a	-US$186m
Mar 31 2023	n/a	n/a	-US$357m
Dec 31 2022	US$13m	US$1m	-US$225m
Sep 30 2022	n/a	n/a	US$254m
Jun 30 2022	n/a	n/a	US$43m
Mar 31 2022	n/a	n/a	-US$407m
Dec 31 2021	US$10m	US$854k	-US$948m
Sep 30 2021	n/a	n/a	-US$1b
Jun 30 2021	n/a	n/a	-US$1b
Mar 31 2021	n/a	n/a	-US$1b
Dec 31 2020	US$4m	US$775k	-US$560m
Sep 30 2020	n/a	n/a	-US$2b
Jun 30 2020	n/a	n/a	-US$2b
Mar 31 2020	n/a	n/a	-US$2b
Dec 31 2019	US$4m	US$769k	-US$2b
Sep 30 2019	n/a	n/a	-US$616m
Jun 30 2019	n/a	n/a	-US$917m
Mar 31 2019	n/a	n/a	-US$2b
Dec 31 2018	US$4m	US$730k	-US$4b

Tazminat ve Piyasa: Tom 'nin toplam tazminatı ($USD 16.24M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.15M ).

Tazminat ve Kazançlar: Tom şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Tom Appio (62 yo)

3yrs

Görev süresi

US$16,239,133

Tazminat

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Appio	CEO & Director	3yrs	US$16.24m	0.17% $ 2.9m
Jean-Jacques Charhon	Executive VP & CFO	less than a year	US$4.27m	Veri yok
Seana Carson	Executive VP & General Counsel	3yrs	US$3.97m	0.043% $ 719.6k
Aimee Lenar	Executive Vice President of US Pharma	less than a year	US$1.99m	Veri yok
Mirza Dautbegovic	Executive VP & COO	3.3yrs	Veri yok	0.036% $ 601.4k
Garen Sarafian	VP & Head of Investor Relations	no data	Veri yok	Veri yok
Kathleen Fitzpatrick	Executive VP and Chief HR & Communications Officer	3.3yrs	Veri yok	Veri yok
Cees Heiman	Senior Vice President of Europe & Canada	3.3yrs	Veri yok	Veri yok
Donald Pearl	Senior Vice President of Ortho Dermatologics	no data	Veri yok	Veri yok
Jiny Kim	Senior Vice President of Solta Medical	2.3yrs	Veri yok	Veri yok
Jonathan Sadeh	Executive VP	less than a year	Veri yok	Veri yok
William Woodfield	Senior VP & Treasurer	no data	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: BHC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Appio	CEO & Director	3yrs	US$16.24m	0.17% $ 2.9m
John Paulson	Independent Chairman	2.9yrs	US$783.74k	0.000060% $ 1.0k
Robert Power	Independent Director	16.8yrs	US$387.50k	0.0018% $ 30.2k
H. Fibiger	Chairman of External Advisory Board	no data	US$2.00m	Veri yok
Sarah Kavanagh	Independent Director	8.8yrs	US$729.99k	0% $ 0
Robert Lenox	Member of the External Advisory Board	16.2yrs	Veri yok	Veri yok
Kathleen Clarence-Smith	Member of the External Advisory Board	16.2yrs	Veri yok	Veri yok
Karoly Nikolich	Member of the External Advisory Board	16.2yrs	Veri yok	Veri yok
Brett Icahn	Independent Director	4.2yrs	US$705.57k	0.00020% $ 3.4k
Amy Wechsler	Independent Director	8.9yrs	US$377.50k	0.011% $ 192.1k
Steven Miller	Independent Director	4.2yrs	US$385.00k	0.028% $ 469.1k
Christian Garcia	Independent Director	1yr	US$329.17k	0% $ 0

8.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BHC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/15 16:10
Gün Sonu Hisse Fiyatı	2025/05/15 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Bausch Health Companies Inc. 39 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Douglas Tsao	Barclays
Ardalan Arfaei	BMO Capital Markets Equity Research
Robert Hazlett	BMO Capital Markets U.S. (Historical)

Bausch Health Companies Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bausch Health Companies Inc., Annual General Meeting, May 13, 2025

Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. Approves Directorate Appointments

Insufficient new directors

Recent updates

Refinancing And New Product Launches Will Unlock Future Possibilities

Price target decreased by 7.1% to US$7.67

First quarter 2025 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. to Report Q1, 2025 Results on Apr 30, 2025

Price target increased by 23% to US$10.86

Bausch Health Companies Inc. Provides Earnings Guidance for the Full Year 2025

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Full year 2024 earnings: EPS exceeds analyst expectations

Revenues Working Against Bausch Health Companies Inc.'s (NYSE:BHC) Share Price

Bausch Health Companies Inc., Annual General Meeting, May 13, 2025

Price target decreased by 7.0% to US$8.83

Bausch Health Companies Inc. to Report Q4, 2024 Results on Feb 19, 2025

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors

Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc